← back to search

J.S. Elborn

Xiamen Tungsten (China) · CN
Area of research
Pulmonary and Respiratory Medicine · Emergency Medical Services
Research interest
Research interests include Cystic Fibrosis Research Advances, Neonatal Respiratory Health Research, Chronic Obstructive Pulmonary Disease (COPD) Research, and Tracheal and airway disorders.
h-index
84
citations
35,067
works
1,114
NIH funding
primary concept
email

Recent publications

Aspergillus Serologic Findings and Clinical Outcomes in Patients With Bronchiectasis: Data From the European Bronchiectasis Registry.
2025cited by 17position: contributordoi
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study
The Lancet Respiratory Medicine 2025cited by 14position: middledoi
Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.
2025cited by 1position: contributordoi
The Association between Bronchiectasis and Chronic Obstructive Pulmonary Disease: Data from the European Bronchiectasis Registry (EMBARC)
American Journal of Respiratory and Critical Care Medicine 2024cited by 38position: middledoi
Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC)
Journal of Allergy and Clinical Immunology 2024cited by 38position: middledoi
Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
European Respiratory Journal 2024cited by 36position: middledoi
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
European Respiratory Journal 2024cited by 26position: middledoi
Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis
iScience 2024cited by 9position: middledoi
Levelling the playing field through the London Network of the UK clinical trials accelerator platform
Contemporary Clinical Trials Communications 2024cited by 4position: contributordoi
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)
The Lancet Respiratory Medicine 2023cited by 267position: middledoi
Bridging the “Know-Do” Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science
Journal of Healthcare Leadership 2023cited by 49position: middledoi
Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis
The Journal of Allergy and Clinical Immunology In Practice 2022cited by 56position: middledoi
Taxonomic position, antibiotic resistance and virulence factor production by Stenotrophomonas isolates from patients with cystic fibrosis and other chronic respiratory infections
BMC Microbiology 2022cited by 26position: middledoi
Bronchiectasis and inhaled tobramycin: A literature review.
2022cited by 24position: contributordoi
Whole-genome analysis of <i>Haemophilus influenzae</i> strains isolated from persons with cystic fibrosis.
2022cited by 4position: contributordoi
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations
The Lancet Respiratory Medicine 2021cited by 276position: middledoi
Characterization of clinical Ralstonia strains and their taxonomic position
Antonie van Leeuwenhoek 2021cited by 47position: middledoi
Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis
European Respiratory Journal 2021cited by 33position: middledoi
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis
Journal of Cystic Fibrosis 2021cited by 26position: contributordoi
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis
Journal of Cystic Fibrosis 2021cited by 19position: firstdoi
Management of chronic <i>Pseudomonas aeruginosa</i> infection with inhaled levofloxacin in people with cystic fibrosis.
2021cited by 12position: contributordoi
Antimicrobial resistance: Concerns of healthcare providers and people with CF.
2021cited by 9position: contributordoi
Therapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult &lt;i&gt;β&lt;/i&gt;ENaC-Tg Mice.
2021cited by 9position: contributordoi
An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT
Programme Grants for Applied Research 2021cited by 9position: contributordoi
An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT
2021cited by 0position: contributor
Lung function and microbiota diversity in cystic fibrosis
Microbiome 2020cited by 265position: middledoi
Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis
Journal of Cystic Fibrosis 2020cited by 53position: contributordoi
Efficacy and safety of TOBI Podhaler in<i>Pseudomonas aeruginosa-</i>infected bronchiectasis patients: iBEST study
European Respiratory Journal 2020cited by 49position: middledoi
Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices.
2020cited by 25position: contributordoi
Finding the relevance of antimicrobial stewardship for cystic fibrosis.
2020cited by 24position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 15 papers (2019–2025) · 8 papers (2013–2022)David E. Geller · Johns Hopkins Medicine7 papers (2013–2019)Félix Ratjen · Hospital for Sick Children7 papers (2013–2020)K. De Boeck · Utrecht University6 papers (2014–2019)Patrick A. Flume · Hospital for Sick Children6 papers (2013–2018)Jane C. Davies · Guy's and St Thomas' NHS Foundation Trust5 papers (2015–2024)Patrick A Flume · Elsevier, Inc.5 papers (2020–2021)Steven M. Rowe · University of Alabama at Birmingham5 papers (2015–2021)Francesco Blasi · University of Haifa5 papers (2015–2025)James D. Chalmers · University of Dundee4 papers (2018–2023)Shawn D. Aaron · Université Laval4 papers (2013–2021) · 4 papers (2015–2019) · 4 papers (2013–2015)Anthony De Soyza · Newcastle University4 papers (2018–2023)Michael W. Konstan · The Ohio State University Wexner Medical Center4 papers (2014–2021)Eitan Kerem · Hadassah Medical Center4 papers (2013–2019)Scott C. Bell · University of Otago4 papers (2015–2019)Judy Bradley · Nutrition Sciences (Belgium)4 papers (2014–2021)Felix C. Ringshausen · Medizinische Hochschule Hannover3 papers (2018–2023)